phosphonoacetic acid has been researched along with Cancer of Colon in 28 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| " Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)." | 2.67 | A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994) |
| "Modulation of the therapeutic efficacy of cisplatin (CDDP) and 5-fluoro-2'-deoxyuridine (FdUrd) alone and in combination with N-phosphonacetyl-L-aspartate (PALA) was evaluated in mice bearing colon carcinoma (C-26) using a weekly intravenous (i." | 1.29 | Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26. ( Cao, S; Durrani, FA; Mayhew, EG; Peters, GJ; Rustum, YM; Van Laar, JA, 1995) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| "Both normal and colonic cancer cells, when cultured in the presence of these agents, cease to increase their cell numbers." | 1.26 | Antiproliferative agents and differential survival between normal and cancer cells. ( Kwong, LK; Tsuboi, KK, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (67.86) | 18.7374 |
| 1990's | 8 (28.57) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Presant, CA | 2 |
| Ardalan, B | 3 |
| Multhauf, P | 1 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 1 |
| Carr, BI | 1 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Bedikian, AY | 1 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| O'Connell, MJ | 3 |
| Rubin, J | 3 |
| Schutt, AJ | 3 |
| Moertel, CG | 4 |
| Kvols, LK | 2 |
| Hahn, RG | 1 |
| Gertz, MA | 1 |
| Erlichman, C | 3 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 2 |
| Weiss, GR | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Karle, JM | 1 |
| Anderson, LW | 1 |
| Cysyk, RL | 1 |
| Van Laar, JA | 2 |
| Mayhew, EG | 1 |
| Cao, S | 1 |
| Durrani, FA | 2 |
| Peters, GJ | 1 |
| Rustum, YM | 2 |
| Seitz, JF | 1 |
| Piedbois, P | 1 |
| Lévy, E | 1 |
| Le Bourgeois, JP | 1 |
| Buyse, M | 1 |
| Jodrell, DI | 1 |
| Oster, W | 1 |
| Kerr, DJ | 1 |
| Canney, PA | 1 |
| Yosef, H | 1 |
| Steward, WP | 1 |
| Kaye, SB | 1 |
| Cassidy, J | 1 |
| Kamm, VJ | 1 |
| Rietjens, IM | 1 |
| Vervoort, J | 1 |
| Heerschap, A | 1 |
| Rosenbusch, G | 1 |
| Hofs, HP | 1 |
| Wagener, DJ | 1 |
| Wadler, S | 1 |
| Mao, X | 1 |
| Bajaj, R | 1 |
| Hallam, S | 1 |
| Schwartz, EL | 1 |
| Kim, JS | 1 |
| Heath, TD | 1 |
| Osieka, R | 1 |
| Houchens, DP | 1 |
| Goldin, A | 1 |
| Johnson, RK | 1 |
| Strong, JM | 1 |
| Wiernik, PH | 1 |
| McAvoy, LM | 1 |
| Cohen, MH | 1 |
| Levine, AS | 1 |
| Hubbard, SM | 1 |
| Tsuboi, KK | 2 |
| Kwong, LK | 2 |
| Edmunds, NH | 1 |
| Bruckner, HW | 1 |
| Motwani, BT | 1 |
| Buroker, TR | 1 |
| Fleming, TR | 1 |
| Everson, LK | 1 |
| Cullinan, SA | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Marschke, RF | 1 |
| Klaassen, DJ | 1 |
| Laurie, JA | 1 |
| Singh, G | 1 |
| Silberman, H | 1 |
| Muggia, FM | 1 |
| Camacho, FJ | 1 |
| Kaplan, BH | 1 |
| Green, MD | 1 |
| Greenwald, ES | 1 |
| Wernz, JC | 1 |
| Engstrom, PF | 1 |
| Chan, TC | 1 |
| Young, B | 1 |
| King, ME | 1 |
| Taetle, R | 1 |
| Howell, SB | 1 |
| Chiuten, DF | 2 |
| Valdivieso, M | 2 |
| Bedikian, A | 2 |
| Bodey, GP | 2 |
| Freireich, EJ | 2 |
| Miller, A | 1 |
| Loo, TL | 1 |
| Benvenuto, JA | 1 |
4 reviews available for phosphonoacetic acid and Cancer of Colon
| Article | Year |
|---|---|
Regional and systemic chemotherapy for advanced colorectal cancer. A review.
Topics: Antineoplastic Agents; Aspartic Acid; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; D | 1983 |
[Chemotherapy in cancers of the colon].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chemotherapy, | 1993 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neopla | 1993 |
Chemotherapy of advanced cancer of the colon and rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Huma | 1991 |
4 trials available for phosphonoacetic acid and Cancer of Colon
| Article | Year |
|---|---|
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials | 1983 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neop | 1994 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
20 other studies available for phosphonoacetic acid and Cancer of Colon
| Article | Year |
|---|---|
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Ataxia; Colonic Neoplasm | 1984 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Humans; Melanoma | 1980 |
Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colonic Neoplasms | 1995 |
Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Aspartic Acid; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Interferon-alpha; Leucovo | 1994 |
N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Base | 1993 |
Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Cytidine Triphosphate; Dose-Respon | 1993 |
In vitro cytotoxic effect of N-(phosphonacetyl)-L-aspartic acid in liposome against C-26 murine colon carcinoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Carriers; Liposomes; Mice; Pa | 2000 |
Chemotherapy of human colon cancer xenografts in athymic nude mice.
Topics: Acridines; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma | 1977 |
Phase I trial of N-(phosphonacetyl)-L-aspartate.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Colonic Neoplasms; Diarrhea; Drug Eruptions; Drug Evaluation | 1979 |
Antiproliferative agents and differential survival between normal and cancer cells.
Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasm | 1978 |
Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
Topics: Animals; Aspartic Acid; Cell Division; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Humans; Ki | 1977 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Modulation of the activity of PALA by dipyridamole.
Topics: Animals; Aspartic Acid; Biological Transport; Cell Line; Colonic Neoplasms; Dipyridamole; Drug Inter | 1985 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |